These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21330904)

  • 1. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection.
    Thorpe J; Saeed S; Moodie EE; Klein MB;
    AIDS; 2011 Apr; 25(7):967-75. PubMed ID: 21330904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.
    Rollet-Kurhajec KC; Moodie EE; Walmsley S; Cooper C; Pick N; Klein MB;
    PLoS One; 2015; 10(6):e0129868. PubMed ID: 26090666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.
    Cooper C; Rollet-Kurhajec KC; Young J; Vasquez C; Tyndall M; Gill J; Pick N; Walmsley S; Klein MB;
    HIV Med; 2015 Jan; 16(1):24-31. PubMed ID: 24837567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
    Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
    BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study.
    Martel-Laferrière V; Nitulescu R; Cox J; Cooper C; Tyndall M; Rouleau D; Walmsley S; Wong L; Klein MB;
    BMC Infect Dis; 2017 Jan; 17(1):80. PubMed ID: 28095797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.
    Tural C; Fuster D; Tor J; Ojanguren I; Sirera G; Ballesteros A; Lasanta JA; Planas R; Rey-Joly C; Clotet B
    J Viral Hepat; 2003 Mar; 10(2):118-25. PubMed ID: 12614468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.
    Potter M; Odueyungbo A; Yang H; Saeed S; Klein MB;
    AIDS; 2010 Jul; 24(12):1857-65. PubMed ID: 20479633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients.
    Li Vecchi V; Soresi M; Colomba C; Mazzola G; Colletti P; Mineo M; Di Carlo P; La Spada E; Vizzini G; Montalto G
    World J Gastroenterol; 2010 Nov; 16(41):5225-32. PubMed ID: 21049556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort.
    Zhang YH; Zhao Y; Rajapaksa US; Lawrence TM; Peng YC; Liu J; Xu K; Hu K; Qin L; Liu N; Sun H; Yan HP; Repapi E; Rowland-Jones S; Thimme R; McKeating JA; Dong T
    PLoS One; 2016; 11(7):e0158037. PubMed ID: 27455208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis.
    Bambha K; Pierce C; Cox C; French AL; Tien PC; Sharp GB; Augenbraun M; Glesby MJ; Villacres MC; Plankey M; Strickler HD; Gange SJ; Peters MG
    AIDS; 2012 Mar; 26(5):599-607. PubMed ID: 22156972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.
    Moodie EE; Pant Pai N; Klein MB
    PLoS One; 2009; 4(2):e4517. PubMed ID: 19223976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed liver fibrosis in HTLV-2-infected patients co-infected with HIV-1 and hepatitis C virus with suppressive antiretroviral therapy.
    Abad-Fernández M; Moreno A; Dronda F; del Campo S; Quereda C; Casado JL; Pérez-Elías MJ; Moreno S; Vallejo A
    AIDS; 2015 Feb; 29(4):401-9. PubMed ID: 25565497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
    Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension.
    Reiberger T; Ferlitsch A; Sieghart W; Kreil A; Breitenecker F; Rieger A; Schmied B; Gangl A; Peck-Radosavljevic M
    J Viral Hepat; 2010 Jun; 17(6):400-9. PubMed ID: 19780945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections.
    Ding Y; Duan S; Ye R; Yang Y; Yao S; Wang J; Cao D; Liu X; Lu L; Jia M; Wu Z; He N
    J Viral Hepat; 2017 May; 24(5):412-420. PubMed ID: 27925409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study.
    Desai SN; Dodge JL; Landay AL; Glesby MJ; Latham PS; Villacres MC; French AL; Gange SJ; Greenblatt RM; Peters MG
    Medicine (Baltimore); 2016 Aug; 95(33):e4483. PubMed ID: 27537569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia.
    Vinikoor MJ; Sinkala E; Mweemba A; Zanolini A; Mulenga L; Sikazwe I; Fried MW; Eron JJ; Wandeler G; Chi BH
    Liver Int; 2015 Jul; 35(7):1886-92. PubMed ID: 25581487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker.
    Al-Mohri H; Murphy T; Lu Y; Lalonde RG; Klein MB
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):463-9. PubMed ID: 17211282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of hepatic fibrosis in HIV/HCV co-infected individuals in Yaoundé, Cameroon: usefulness of APRI score in resource-constrained settings.
    Dobseu R; Nanfack A; Kowo M; Ambada G; Kamgaing R; Chenwi C; Fainguem N; Ka'e A; Ngangoum E; Sosso S; Tchiegang C; Ndjolo A
    BMC Infect Dis; 2020 Oct; 20(1):758. PubMed ID: 33059627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. There is no difference in hepatic fibrosis rates of patients infected with hepatitis C virus and those co-infected with HIV.
    Souza AR; Tovo CV; Mattos AA; Chaves S
    Braz J Med Biol Res; 2008 Mar; 41(3):223-8. PubMed ID: 18176724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.